<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<!-- saved from url=(0120)http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0206/0206_q2/0206_i3?f=templates&fn=document-frame.htm&2.0 -->
<HTML><HEAD><TITLE>Clinical Evidence</TITLE>
<META http-equiv=Content-Type content="text/html; charset=windows-1252">
<LINK 
href="0206_i3_files/bmj.css" type=text/css rel=stylesheet>
<META content="MSHTML 5.50.4807.2300" name=GENERATOR></HEAD>
<BODY topMargin=0>
<TABLE cellSpacing=0 borderColorDark=#ffffff cellPadding=0 width="100%" 
borderColorLight=#c2c2c2 border=1>
  <TBODY>
  <TR>
    <TD class=heading id=heading>
      <SCRIPT src="0206_i3_files/0206_i3.0"></SCRIPT>

      <SCRIPT language=JavaScript> function showWindow(targeturl) { window.open(targeturl, ""); } </SCRIPT>

      <TABLE width="100%" border=0>
        <TBODY>
        <TR>
              <TD align=right><SPAN class=localheadtopic 
            id=localheadtopic><SECTION>Cardiovascular disorders</SECTION></SPAN><IMG height=10 
            src="0206_i3_files/spacer.gif" width=10 align=absMiddle 
            border=0><BR>
                <SPAN class=localhead id=localhead><TOPIC>Secondary prevention 
                of ischaemic cardiac events</TOPIC><IMG height=10 
            src="0206_i3_files/spacer.gif" width=10 align=absMiddle 
            border=0></SPAN></TD>
            </TR>
        <TR>
              <TD class=title-author id=title-author vAlign=top noWrap align=right 
          bgColor=#ffffff height=30><A 
            href="http://www.evidence.org/lpBinCE/lpext.dll?f=id&amp;id=0206_CONTRIB&amp;t=document-frame.htm&amp;2.0&amp;p="><EM>Clinical 
                Evidence</EM> writers on secondary prevention of ischaemic cardiac 
                events</A><IMG height=10 src="0206_i3_files/spacer.gif" width=10 
            align=absMiddle border=0></TD>
</TR></TBODY></TABLE><BR>
      <H1 style="DISPLAY: none; FONT-SIZE: 0pt; VISIBILITY: hidden">Other 
      drugs</H1>
      <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
        <TBODY>
        <TR>
          <TD class=question id=question vAlign=top width="10%"><B><SPAN 
            class=question-title id=question-title>QUESTION</SPAN></B></TD>
          <TD class=question id=question>&nbsp;<B>What are the effects of 
            other drug treatments?</B></TD></TR></TBODY></TABLE><BR><A name=I3>
      <H2 style="DISPLAY: none; FONT-SIZE: 0pt; VISIBILITY: hidden">ß 
      Blockers</H2>
      <TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
        <TBODY>
        <TR class=option id=option>
          <TD class=option id=option style="PADDING-LEFT: 2px" vAlign=top 
          width="10%"><SPAN class=option-title 
            id=option-title>OPTION&nbsp;&nbsp;&nbsp;</SPAN></TD>
          <TD class=option id=option style="PADDING-LEFT: 2px" 
            width="100%"><B>ß Blockers</B></TD></TR></TBODY></TABLE></A>
      <TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
        <TBODY>
        <TR>
          <TD><A name=I3-SUMSTATEMENT><B>
            <P style="MARGIN-LEFT: 3px" align=justify>We found strong evidence 
            from systematic reviews of RCTs that ß blockers reduce the risk of 
            all cause mortality, coronary mortality, recurrent non-fatal MI, and 
            sudden death in people after MI. Most benefit was seen in those at 
            highest risk of death after an MI (&gt;&nbsp;50 years old; previous 
            MI, angina pectoris, hypertension, or treatment with digitalis; 
            transient mechanical or electrical failure; higher heart rate at 
            study entry). About a quarter of people suffered adverse 
            effects.</P></B></A></TD></TR></TBODY></TABLE><BR>
      <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
        <TBODY>
        <TR>
          <TD>
            <P align=justify><FONT color=#0033cc><A 
            name=I3-BENEFITS><B>Benefits: </B></A></FONT><B>Survival and 
            reinfarction:</B> One systematic review (search date 1993, 26 RCTs, 
            over 24&nbsp;000 people) compared oral ß blockers versus placebo 
            within days or weeks of an acute MI (late intervention trials) and 
            continued for between 6 weeks to 3 years. Most RCTs followed 
            participants for 1 year. The review found improved survival in 
            people given ß blockers (RRR 23%, 95% CI 14% to 30%). <A 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0206/0206_q2/0206_i3?f=templates&amp;fn=document-frame.htm&amp;2.0#REF23">[23]</A> 
            One prior systematic review (search date not stated, 24 RCTs) found 
            that long term use of ß blockers versus placebo after MI reduced 
            total mortality (RRR about 20%; NNT 48), sudden death (RRR about 
            30%; NNT 63), and non-fatal reinfarction (RRR about 25%; NNT 56). <A 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0206/0206_q2/0206_i3?f=templates&amp;fn=document-frame.htm&amp;2.0#REF24">[24]</A> 
            <B>Anginal symptoms:</B> We found no good RCTs evaluating the 
            antianginal effects of ß blockers in people after MI. One trial 
            found atenolol more effective than placebo in people with chronic 
            stable effort angina or silent ischaemia. <A 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0206/0206_q2/0206_i3?f=templates&amp;fn=document-frame.htm&amp;2.0#REF25">[25]</A> 
            <B>Different types of ß blockers:</B> The earlier review found no 
            differences between ß blockers with and without cardioselectivity or 
            membrane stabilising properties, but it raised concerns about the 
            lack of efficacy of ß blockers with intrinsic sympathomimetic 
            activity in long term management after MI. <A 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0206/0206_q2/0206_i3?f=templates&amp;fn=document-frame.htm&amp;2.0#REF24">[24]</A> 
            One RCT (607 people after MI) found that acebutolol, a ß blocker 
            with moderate partial agonist activity, decreased 1 year mortality 
            compared with placebo (AR of death: 11% with placebo, 6% with 
            acebutolol; RRR 48%, 95% CI 9% to 71%). <A 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0206/0206_q2/0206_i3?f=templates&amp;fn=document-frame.htm&amp;2.0#REF26">[26]</A> 
            <B>Effects in different subgroups:</B> One systematic review (search 
            date 1983, 9 RCTs) compared ß blockers versus placebo started more 
            than 24 hours after onset of symptoms of acute MI and continued for 
            9–24 months. <A 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0206/0206_q2/0206_i3?f=templates&amp;fn=document-frame.htm&amp;2.0#REF27">[27]</A> 
            Pooled analysis of individual data (13&nbsp;679 people) found that 
            the benefits of ß blockers versus placebo on mortality seemed 
            comparable in men and women. The highest absolute benefit from ß 
            blockers was found in subgroups with the highest baseline risks 
            (that is, those with the highest mortality on placebo): those over 
            50 years of age; those with a history of previous MI, angina 
            pectoris, hypertension, or treatment with digitalis; those with 
            transient signs or symptoms of mechanical or electrical failure in 
            the early phases of MI; and those with a higher heart rate at study 
            entry. Low risk subgroups had smaller mean absolute 
        benefit.</P></TD></TR></TBODY></TABLE>
      <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
        <TBODY>
        <TR>
          <TD>
            <P align=justify><FONT color=#0033cc><A name=I3-HARMS><B>Harms: 
            </B></A></FONT>Adverse effects include shortness of breath, 
            bronchospasm, bradycardia, hypotension, heart block, cold hands and 
            feet, diarrhoea, fatigue, reduced sexual activity, depression, 
            nightmares, faintness, insomnia, blacking out, and hallucinations. 
            Rates vary in different studies. One RCT reported an absolute risk 
            increase for any adverse effect on propranolol compared with placebo 
            of 24% (95% CI not available). Serious adverse effects were uncommon 
            and only a small proportion of people withdrew as a result. <A 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0206/0206_q2/0206_i3?f=templates&amp;fn=document-frame.htm&amp;2.0#REF28">[28]</A> 
            </P></TD></TR></TBODY></TABLE>
      <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
        <TBODY>
        <TR>
          <TD>
            <P align=justify><FONT color=#0033cc><A name=I3-COMMENT><B>Comment: 
            </B></A></FONT>Continued benefit has been reported from the use of ß 
            blockers up to 6 years after MI (ARR for mortality 5.9%, 95% CI not 
            available; P&nbsp;=&nbsp;0.003; RRR 18%). However, the study was not 
            blinded after 33 months.</P></TD></TR></TBODY></TABLE><BR><A 
      name=references></A>
      <TABLE cellSpacing=0 cellPadding=0 border=0>
        <TBODY>
        <TR>
          <TD width=90 bgColor=#404040><IMG height=2 src="" width=1 
            align=absMiddle border=0></TD>
          <TD vAlign=bottom width="100%" bgColor=#404040><IMG height=2 src="" 
            width=1 align=absMiddle border=0></TD></TR>
        <TR>
          <TD class=key-message id=key-message width=90 
            bgColor=#404040><B>References</B></TD>
          <TD width="100%">&nbsp;</TD></TR></TBODY></TABLE><BR>
      <TABLE cellPadding=2 width="100%" align=center>
        <TBODY>
        <TR><A class=reference id=reference name=REF23></a>
          <TD class=reference id=reference vAlign=top width=15>23. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Teo KK, 
            Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug 
            therapy in acute myocardial infarction. <EM>JAMA</EM> 
            1993;270:1589–1595. Search date 1993; primary sources Medline; hand 
            search of reference lists; details of unpublished trials sought from 
            pharmaceutical industry/other investigators. <A 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=93381966");' 
            style="FONT-SIZE: 8pt">[PubMed]</A></TD></TR>
        <TR><A class=reference id=reference name=REF24></a>
          <TD class=reference id=reference vAlign=top width=15>24. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Yusuf S, 
            Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and 
            after myocardial infarction: An overview of the randomized trials. 
            <EM>Prog Cardiovasc Dis</EM> 1985;27:335–371. No details of search 
            date or primary sources given.</TD></TR>
        <TR><A class=reference id=reference name=REF25></a>
          <TD class=reference id=reference vAlign=top width=15>25. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Pepine CJ, 
            Cohn PF, Deedwania PC, et al for the ASIST Study Group. Effects of 
            treatment on outcome in mildly symptomatic patients with ischemia 
            during daily life: the atenolol silent ischemia study (ASIST). 
            <EM>Circulation</EM> 1994;90:762–768. <A 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=94320250");' style="FONT-SIZE: 8pt">[PubMed]</A></TD></TR>
        <TR><A class=reference id=reference name=REF26></a>
          <TD class=reference id=reference vAlign=top width=15>26. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Boissel 
            J-P, Leizerovicz A, Picolet H, et al, for the APSI Investigators. 
            Secondary prevention after high-risk acute myocardial infarction 
            with low-dose acebutolol. <EM>Am J Cardiol</EM> 1990;66:251–260. <A 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=90313637");' 
            style="FONT-SIZE: 8pt">[PubMed]</A></TD></TR>
        <TR><A class=reference id=reference name=REF27></a>
          <TD class=reference id=reference vAlign=top width=15>27. </TD>
          <TD class=reference id=reference vAlign=top width="100%">The 
            Beta-Blocker Pooling Project Research Group. The beta-blocker 
            pooling project (BBPP): subgroup findings from randomized trials in 
            post infarction patients. <EM>Eur Heart J</EM> 1988;9:8–16. Search 
            date placebo controlled trials published by December 1983; details 
            of primary sources not given. <A 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=AMBIGUOUS 89210943, 88152021");' style="FONT-SIZE: 8pt">[PubMed]</A></TD></TR>
        <TR><A class=reference id=reference name=REF28></a>
          <TD class=reference id=reference vAlign=top width=15>28. </TD>
          <TD class=reference id=reference vAlign=top 
            width="100%">Beta-blocker Heart Attack Trial Research Group. A 
            randomized trial of propranolol in patients with acute myocardial 
            infarction: I. Mortality results. <EM>JAMA</EM> 1982;247:1707–1714. 
            <A 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=82145830");' style="FONT-SIZE: 8pt">[PubMed]</A></TD></TR></TBODY></TABLE>
      <TABLE width="100%" border=0>
        <TBODY>
        <TR>
          <TD vAlign=bottom width="50%">
              <TD align=right width="50%"><A 
            href="http://www.evidence.org/lpBinCE/lpext.dll?f=id&amp;id=201106&amp;t=document-frame.htm&amp;p=copyright.html&amp;2.0"><IMG 
            alt="BMJ - Clinical Evidence" src="0206_i3_files/ce-pagebrand.jpg" 
            border=0></A></TD>
</TR>
        <TR>
          <TD align=left width="50%">
          <TD align=right width="50%"><A 
            href="http://www.evidence.org/lpBinCE/lpext.dll?f=id&amp;id=201106&amp;t=document-frame.htm&amp;p=copyright.html&amp;2.0"><SPAN 
            style="FONT-SIZE: 8pt; font-face: arial">© 2001 BMJ Publishing 
            Group</SPAN></A></TD></TR></TBODY></TABLE>
      <SCRIPT language=JavaScript>
			var purl = "0206.PDF"; 
</SCRIPT>

      <SCRIPT language=JavaScript src="0206_i3_files/stats.js" 
      type=text/javascript></SCRIPT>

      <SCRIPT language=JavaScript type=text/javascript><!--
  stats("MC-MTg0OQ==-45MT-Y2Nz","","","");
//--></SCRIPT>
      <NOSCRIPT><IMG height=1 src="" width=1 
  border=0></NOSCRIPT></TD></TR></TBODY></TABLE>
<FORM name=LPHitCountForm><INPUT type=hidden value=0 name=LPHitCount> 
</FORM></BODY></HTML>
